This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Obecure Is Granted Methods And Composition Patents Covering Adjunctive Use Of Betahistine To Mitigate Weight Gain Associated With Olanzapine

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd. (TASE:BOLT), has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

Obecure is focused on development of Histalean ® (high dose betahistine) as adjunctive to antipsychotic drug therapy for improved treatment of schizophrenia, bipolar disorder and major depression. Obecure has recently announced the outcomes of randomized, placebo controlled Phase 1b and pilot Phase 2 trials, showing that co-administration of Histalean ® with olanzapine (Zyprexa ®), safely and significantly reduced weight gain and somnolence, two of the most serious side effects associated with this drug, as with most of the second generation antipsychotics as a drug class, also including risperidone (Risperdal ®), quetiapine (Seroquel ®) and aripiprazole (Abilify ®).

These antipsychotic drugs are widely used to relieve symptoms of serious psychiatric diseases including schizophrenia, bipolar disease and major depression with cumulative prevalence >5% and early onset in adolescence and even childhood. However, in recent years there has been growing concern of regulators and practitioners about these drugs’ induction of weight gain. Recent publications suggest that olanzapine causes an average weight gain of about 8 kg in just 12 weeks. This not only reduces patients’ compliance, but also exposes them to metabolic syndrome, diabetes and cardiovascular disorders; a concern which has resulted in FDA’s issuance of black box warnings, and which has greatly affected prescription decisions. Moreover, daytime sleepiness (somnolence) induced by these drugs is seriously impacting patients quality of life – prohibiting driving, hampering their ability to hold jobs and/or continue with their education.

“The allowance of our leading US patents validate the novelty and practicality of our approach and are serving as the initial milestone in our evolving intellectual property” said Dr. Yaffa Beck, CEO of Obecure, adding that “Olanzapine is considered the most effective of the first line antipsychotic drugs, but is also known to cause substantial weight gain. It is thus the first drug we focused on.” The patent portfolio includes applications pending worldwide, covering methods and compositions of betahistine for management of weight and somnolence that are secondary side effects of most psychiatric drugs.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BOLT $5.60 0.00%
AAPL $93.51 -1.40%
FB $116.91 0.15%
GOOG $694.22 0.46%
TSLA $246.17 -0.62%


Chart of I:DJI
DOW 17,722.21 -108.55 -0.61%
S&P 500 2,061.89 -13.92 -0.67%
NASDAQ 4,772.9380 -32.3530 -0.67%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs